These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29547591)

  • 1. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
    Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
    Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
    Roberts LS; Yan P; Bateman LA; Nomura DK
    ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
    Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
    Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer
    Gao Z; Wang T; Li R; Du Y; Lv H; Zhang L; Chen H; Shi X; Li Q; Shen J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):125-134. PubMed ID: 34894977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
    Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
    Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
    Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
    Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
    Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
    Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
    Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
    Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
    Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells.
    Robles AJ; McCowen S; Cai S; Glassman M; Ruiz F; Cichewicz RH; McHardy SF; Mooberry SL
    J Med Chem; 2017 Nov; 60(22):9275-9289. PubMed ID: 29053266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.